1. FDA Fast-Tracks Three Psychedelic Treatments for Depression and PTSD in Rare Policy Shift
The Food and Drug Administration is accelerating its review of three psychedelic-based treatments for mental health disorders, marking a notable shift in the agency's approach to these controversial yet increasingly studied substances. The agency granted priority review vouchers to Compass Pathways, the Usona Institute...